ThuJul 30th, 2020
Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress
Lantern Pharma Reports Second Quarter 2020 Financial Results and [...]
FriJul 24th, 2020
Lantern Pharma to Host Second Quarter 2020 Operating and Financial Results Conference Call on July 30, 2020
Lantern Pharma to Host Second Quarter 2020 Operating and [...]
MonJul 20th, 2020
Lantern Pharma Establishes Manufacturing Network in Preparation for Its Phase 2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and a Phase 1 Clinical Trial for Solid Tumors and Glioblastoma
Lantern Pharma Establishes Manufacturing Network in Preparation for Its [...]
MonJun 29th, 2020
Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 450 Million Datapoints, Ahead of Schedule, and Accelerates the Company’s Path to 1 Billion Datapoints Curated Specifically for Oncology Drug Development and Drug Response Prediction
Lantern Pharma’s Proprietary A.I. Platform for Precision Oncology Drug [...]
WedJun 17th, 2020
Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting
Lantern Pharma to update leading cancer researchers and healthcare [...]
MonJun 15th, 2020
Lantern Pharma Announces Closing of Initial Public Offering
Lantern Pharma Announces Closing of Initial Public Offering June [...]